SWOG clinical trial number

An Intergroup Phase II Clinical Trial for Adolescents and Young Adults with Untreated Acute Lymphoblastic Leukemia (ALL)

Abbreviated Title
Phase II Adolescent/Young Adult with Untreated ALL
Status Notes
Permanent Closure Effective 9/14/12

NCORP, Members, Medical Oncologists, Pathologists, Affiliates

Research committees



Cytosine Arabinoside Cyclophosphamide Dexamethasone Vincristine 6-Mercaptopurine 6-Thioguanine Allopurinol Daunomycin Doxorubicin Leucovorin Calcium Methotrexate Trimethoprim sulfa PEG-L-Asparaginase

Eligibility Criteria Expand/Collapse

Newly diagnosed ALL with B or T-precursor. Pts with Burkitt type leukemia not eligible. 16 to 29 years (inclusive). 0-2 performance status. Pts with Down Syndrome not eligible. No prior therapy for ALL except emergency therapy (corticosteroids or hydroxyurea) for blast cell crisis, superior vena cava dyndrome or renal failure due to leukemic infiltration of kidneys. Single-dose intrathecal cytarabine allowed. (Chemo must begin within 72 hours of dose). Prior steroid therapy allowed but must be documented.

Publication Information Expand/Collapse


A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403

W Stock;S Luger;A Advani;J Yin;R Harvey;C Mullighan;C Willman;N Fulton;K Laumann;M Malnassy;E Paietta;E Parker;S Geyer;K Mrozek;C Bloomfield;B Sanford;G Marcucci;M Liedtke;D Claxton;M Foster;J Bogart;J Grecula;F Appelbaum;H Erba;M Litzow;M Tallman;R Stone;R Larson Blood Apr 4;133(14):1548-1559

PMid: PMID30658992 | PMC number: PMC6450431


An inherited genetic variant in CEP72 promoter predisposes to vincristine-induced peripheral neuropathy in adults with acute lymphoblastic leukemia

W Stock;B Diouf;KR Crews;D Pei;C Cheng;K Laumann;S Mandrekar;S Luger;A Advani;RM Stone;RA Larson;WE Evans Clinical Pharmacology and Therapeutics 2017 Mar;101(3):391-395. Epub 2016 Nov 16.

PMid: PMID27618250 | PMC number: PMC5320866


Favorable outcomes for adolescents and young adults (AYA) with acute lymphoblastic leukemia (ALL): early results of US intergroup trial CALGB 10403 (Alliance)

W Stock;S Geyer;S Luger;A Advani;R Harvey;C Mullighan;C Willman;E August Parker;K Laumann;BL Sanford;G Marcucci;E Paietta;MS Tallman;FR Appelbaum;HP Erba;M Litzow;R Stone;RA Larson Blood 124(21):796;American Society for Hematology (December 6-9, 2014, San Francisco, CA), oral;


Frontline treatment of acute lymphoblastic leukemia (ALL) in older adolescents and young adults (AYA) using a pediatric regimen is feasible: toxicity results of the prospective US intergroup trial CALGB 10403 (Alliance)

A Advani;B Sanford;S Luger;M Devidas;E Larsen;M Liedtke;p Voorhees;M Foster;D Claxton;E Parker;K Coffan;W Carroll;N Winik;S Coutre;M Tallman;F Appelbaum;H Erba;R Stone;S Hunger;RA Larson;W Stock Blood 122:1443; American Society of Hematology annual meeting (Dec 7-10, 2013, New Orleans, LA), poster;


Who participates in an adult cooperative group trial for adolescent and young adults (AYAs)? Baseline demographic and psychosocial characteristics of AYAs enrolled on intergroup trial C10403 for acute lymphoblastic leukemia (ALL)

L Muffly;W Stock;A Breitenbach;S Mulkey;S Luger;A Advani;E Parker;MC Foster;M Liedtke;R Garcia;K Coffan;J Sipin-Sayno;J McNeer;M Tallman;F Appelbaum;R Stone;R Larson Blood 120(21):abst.3535; American Society of Hematology Annual Meeting, poster presentation


Older adolescents and young adults with acute lymphoblastic leukemia (ALL) in the United States: from the lowest to highest death rate and number of deaths -- more rationale for the CALBG-WSOG-ECOG C10403 trial based on COG AALL0232

WA Bleyer Journal of Clinical Oncology 26(15s):abstr. #18034